CD209 and cancer: Thus, lentiviral vectors are attractive vaccine modalities for induction of robust T cell responses against infectious disease and cancer.42, 43, 44 We evaluated a novel third-generation lentiviral vector designated ZVex, which selectively targets DCs via interaction of its Sindbis-virus-derived envelope protein with the receptor DC-specific intercellular adhesion molecule (ICAM)-3 grabbing non-integrin DC-SIGN (CD209) expressed on immature DCs and is currently being advanced in cancer immunotherapy trials.